Roivant Sciences is trading at $36.62, down 4.21%, in a move most consistent with broad risk-off selling amid investor concerns about AI spending and scrutiny of data-center expansion. - No clear Roivant Sciences-specific catalyst for the November 5 decline surfaced in the search; Reuters reported the Nasdaq fell nearly 4% during the session. - The supplied sector data shows XBI down 5.19%. - Prior positive brepocitinib trial news does not explain the day’s drop.